AdvaMed Pushes State Lobbying Actions
This article was originally published in The Gray Sheet
The national trade group and regional trade associations unveiled a state-based “competitiveness agenda” last week, partially in response to frustrations at the federal level.
You may also be interested in...
Not-So-Happy New Year: Device Tax Not Addressed In Fiscal Cliff Law
There’s no mention of a device tax delay or repeal in the measure signed by President Obama Jan. 2, and the new law contains some Medicare payment cuts as one-year “Doc Fix” pay-fors.
ImmunoGen’s Elahere Data In Avastin-Naïve Ovarian Cancer Prompt Discussion About Earlier Use
The presenter on the MIRASOL study called the data “practice changing,” while the discussant cited Sutro’s STRO-002 as a potential option for patients with low folate receptor alpha expression.
ASCO - Servier’s Vorasidenib Puts The Brakes On Brain Cancer In INDIGO
Servier’s targeted therapy, vorasidenib, can effectively delay the need for more drastic treatment in patients with low-grade glioma, but increases in liver enzymes including two cases of Hy’s law have cast some shade over the INDIGO data.